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Prefazione  
“Abbiamo spesso sentito sostenere la tesi che le scienze sono fondate su concetti 
basilari chiari e nettamente definiti. In verità nessuna scienza, neanche la più esatta, 
inizia con tali definizioni. Il vero inizio dell’attività scientifica consiste piuttosto nel 
descrivere i fenomeni e quindi nel raggrupparli, classificarli e correlarli. Già allo stadio 
di descrizione non è possibile evitare di applicare certe idee astratte al materiale in 
questione, che derivano da qualche parte, ma che certamente sono basate 
unicamente sulle nuove osservazioni. Tali idee –che in seguito diventeranno I concetti 
basilari della scienza- sono ancora più indispensabili quando il materiale viene 
ulteriormente elaborato. Dapprima esse devono necessariamente possedere un certo 
grado di indefinitezza; non si può neanche considerare una chiara delimitazione del 
loro contenuto. Finché queste idee rimangono in questo stato, noi arriviamo a capirne 
il significato facendo spesso riferimento al materiale di osservazione da cui sembra 
scaturire, ma al quale, in realtà, sono state imposte. Così a rigor di termini, esse non 
sono che convenzioni, benché tutto dipenda dal fatto che non sono scelte 
arbitrariamente, ma determinate in dipendenza dai loro rapporti che noi intuiamo 
anche prima di poterli riconoscere e dimostrare. Siamo in grado di formulare i basilari 
concetti scientifici con maggior precisione solo dopo un’indagine più profonda del 
campo di osservazione, e progressivamente possiamo modificarli sicché diventino utili 
e coerenti quando vengono applicati a un’area più estesa. A quel punto è arrivato il 
momento di regalarli alla scienza. Il progresso della scienza, comunque, non tollera 
alcuna rigidità nemmeno nelle definizioni. La fisica e la chimica forniscono degli 
eccellenti esempi di definizioni che vanno sempre alterati nel loro contenuto.”     
 
Sigmund Freud- Metapsicologia 
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Abstract  
This thesis reports an integrated analytical and physicochemical approach for the study of 
natural substances and new drugs based on mass spectrometry techniques combined with 
liquid chromatography. 
In particular, Chapter 1 concerns the study of Berberine a natural substance with 
pharmacological activity for the treatment of hepatobiliary and intestinal diseases. The 
first part focused on the relationships between physicochemical properties, 
pharmacokinetics and metabolism of Berberine and its metabolites. For this purpose a 
sensitive  HPLC-ES-MS/MS method have been developed, validated and used to determine 
these compounds during their  physicochemical properties studies and plasma levels of 
berberine and its metabolites including berberrubine(M1), demethylenberberine(M3), and 
jatrorrhizine(M4) in humans. Data show that M1, could have an efficient intestinal 
absorption by passive diffusion due to a keto-enol tautomerism confirmed by NMR studies 
and its higher plasma concentration.  In the second part of Chapter 1, a comparison 
between M1 and BBR in vivo biodistribution in rat has been studied. 
In Chapter 2 a new HPLC-ES-MS/MS method for the simultaneous determination and 
quantification of glucosinolates, as glucoraphanin, glucoerucin and sinigrin, and 
isothiocyanates, as sulforaphane and erucin, has developed and validated. This method 
has been used for the analysis of functional foods enriched with vegetable extracts.  
Chapter 3 focused on a physicochemical study of the interaction between the bile acid 
sequestrants used in the treatment of hypercholesterolemia including colesevelam and 
cholestyramine with obeticolic acid (OCA), potent agonist of nuclear receptor farnesoid X 
(FXR). In particular, a new experimental model for the determination of equilibrium 
binding isotherm was developed.  
Chapter 4 focused on methodological aspects of new hard ionization coupled with liquid 
chromatography (Direct-EI-UHPLC-MS) not yet commercially available and potentially 
useful for qualitative analysis and for “transparent” molecules to soft ionization 
techniques. This method was applied to the analysis of several steroid derivatives. 
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Chapter 1 
Nutraceutical: berberine and its 
metabolites 
In recent years, there is a growing interest in "nutraceuticals" which provide health 
benefits and are alternative or complementary to the use of conventional drugs in 
modern medicine. The term “nutraceutical” was coined from “nutrition” and 
“pharmaceutical”. According to DeFelice definition, nutraceutical can be defined “as a 
food (or part of a food) that provides medical or health benefits, including the 
prevention and/or treatment of several diseases”1. 
In this definition, nutrients, herbals and dietary supplements, that contain one or more 
bioactive molecules, are included.  Most commercially nutraceuticals contain a single 
purified natural substance perpetrated from raw extracts in different foods products. 
The active ingredient often exceeds the amount present in the whole plant. Indeed, 
the rationale used in nutraceutical field is that the administered doses of these 
supplements should be as high as in conventional drugs. In this way, a nutraceutical 
and a drug could have the same therapeutic effect. Nevertheless unlike drugs, 
nutraceuticals do not require conventional approval based on a detailed 
characterization (toxicological studies, metabolism) of its constituents, undermining 
the consumers’ safety. Indeed, often the non- declared compounds are present in 
these supplements even at higher amount than the declared bioactive molecule. To 
make matters worse, their physicochemical properties, biodistribution in the human 
body and target organ activity have been poorly studied despite nutraceuticals 
administration at high doses (from 0.5 to 2g/day). The row material and natural extract 
could be purchased by uncontrolled suppliers and this is an additional concern for the 
consumer’s safety. 
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1.1 Berberine   
1.1.1 Pharmacological and therapeutic effects  
Berberis vulgaris L. extracts have been used for a long time in traditional Indian and 
Chinese medicine used as antimicrobial against a variety of organisms such as bacteria, 
viruses, fungi, protozoans, helminthes, and chlamydia2. Studies carried out on the 
chemical composition of these extracts show that the major isoquinoline alkaloid 
constituents were berberine and palmitine. Recently, Berberine (BBR, Figure 1) has 
intrigued increasing interest in its several bioactivities as antifungal3, anti-
inflammatory4, antimalarial5, anti-HIV6, antihyperglycemic7, immunoregulatory8, 
antitumor9. 
Clinical trials showed also the beneficial effects of berberine in hypercholesterolemic 
patients and type 2 diabetes10. Indeed, administration of Berberine 500mg/die 
decreased the levels of total cholesterol, LDL-cholesterol and triglycerides (i.e. about 
29, 25 and 35%). In particular, BBR increase low-density-lipoprotein receptor (LDLR) 
expression by stabilization of LDLR mRNA by activation of extracellular signal-regulated 
kinase (ERK). In addition, BBR was active in enhancing the expression of insulin 
receptor (InsR).  
 
 
1.1.2 Metabolism of berberine 
Previous studies11 showed that BBR is metabolized in the liver by CYP450 isoenzymes 
through oxidative demethylation at positions 2, 3, 9, and 10 followed by conjugation of 
these hydroxyl group functions with glucuronic acid.  In humans, the main primary 
metabolites of BBR  
Figure 1) report the chemical structure of the main metabolites berberrubine (M1), 
thalifendine (M2), demethyleneberberine (M3), and jatrorrhizine (M4).  
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Figure 1. Primary hepatic metabolism of BBR 
 
As well as BBR, its metabolites exhibit some pharmacological properties such as up-
regulation of low-density lipoprotein receptor, and mRNA expression12. Among these, 
M1 showed the best up-regulatory effect for LDLR mRNA expression, although its 
activity was lower than BBR (Figure 2). Toxicity studies of metabolites have not yet 
been carried out as well as have not been evaluated their possible side effects. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of BBR and its metabolites on LDLR gene expression 
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1.1.3 Aim and rationale 
Protoberberine (5,6-dihydrodibenzo[a,g]quinolizinium), alkaloids found in the bark, 
rhizomes, roots, and stems of Berberis vulgaris L. (Berberidaceae)2, show many 
different types of biological activities. Among them, berberine (BBR, Figure 1) is the 
most interesting compound, which has a multi-target activity in particular as 
cholesterol-lowering effect10.   
In the last 20 years the study of natural substances has changed radically, but 
nowadays is still lacking a complete physicochemical characterization of biologically 
active natural molecules and even more of its major metabolites in vivo. This fact 
represents a bottleneck in lead discovery for pharmaceutical research based on natural 
sources. Indeed, the importance of physicochemical properties of molecules in the 
development of orally bioavailable drugs has been recognized. Even though 
nutraceuticals do not require a conventional drug approval for which pharmacokinetic, 
metabolism and safety studies must be conducted.  
For this reasons, the aim of this study is to develop and validate a new HPLC-ES-MS/MS 
method for the qualitative and quantitative determination of BBR and its metabolites. 
This method will be used to accurately quantify BBR and its metabolites during studies 
regarding the measurements of their physicochemical properties, including 
lipophilicity, solubility, pKa, and albumin binding. 
 In addition, to better understand BBR and its metabolites pharmacokinetic, intestinal 
absorption and biodistribution in target organs, the plasma levels of BBR and its 
metabolites after acute and chronic oral administration to hypercolesterolemic 
patients will be investigated. The biomarker of hypercholesterolemia activity (total, 
LDL and HDL cholesterol, total triglycerides) will be monitored in hypercolesterolemic 
patients chronically treated with BBR.  
Finally, the relationship between the plasma levels and physicochemical properties of 
BBR and its metabolites will be critically discussed.  
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1.1.4 Experimental 
1.1.4.1 Materials and reagents 
Berberine chloride (BBR-Cl) and jatrorrhizine chloride (M4-Cl), as a standard for HPLC 
(purity ≥97%), were purchased from Sigma (St. Louis, MO, USA) and AlloraChem srl 
(Rimini, Italy) respectively.  
Berberrubine and demethylberberine were synthetized in Prof. M. Roberti Laboratory 
(Department of Pharmacy and Biotechnology, University of Bologna). Flash column 
chromatography was performed on silica gel (particle size 40−63 μm, Merck). (R,S)-
noscapine, used as internal standard and Tris-HCl salt were purchased from Sigma (St. 
Louis, MO, USA).   
The organic solvents used have HPLC-grade: methanol and acetonitrile were purchased 
from Carlo Erba Reagents (Milan, Italy) and LiChrosolv. HPLC-grade water was 
prepared using the Millipore Milli-Q Synthesis A10 system (Molsheim, France).   
Berberis Vulgaris 250 mg capsules were purchased from KOS s.r.l. (Comeana, Italy). 
Oasis HLB (hydrophilic−lipophilic balance 200 mg, 6 mL) SPE columns were purchased 
from Waters (Milan, Italy)  
 
 
1.1.4.2 Synthesis of berberine metabolites  
Berberrubine 
Berberrubine chloride was prepared starting from berberine chloride following two 
different procedures, reported in Figure 3. In particular, in the first procedure (a) 
berberrubine chloride was obtained  by berberine chloride pyrolysis, heated at 195°-
200° C for 10-15 min, in solvent-free conditions under vacuum13 (20-30 mmHg), 
washed with ethanol and filtered (yield 81%).  
 
1H-NMR (DMSO-d6, 400 MHz): δ 3.10 (t, 2H, J= 6.0 Hz), 3.79 (s, 3H), 4.54 (t, 2H, J= 6.0 
Hz), 6.16 (s, 2H), 6.41 (d, 1H, J= 8 Hz), 7.02 (s, 1H), 7.27 (d, 1H, J= 8 Hz), 7.67 (s, 1H), 
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8.04 (s, 1H), 9.14 (s, 1H). 13C-NMR (DMSO-d6, 100 MHz): δ 27.5, 52.3, 55.7, 100.6, 
101.5, 104.7, 108.2, 117.1, 120.0, 121.2, 121.8, 129.2, 132.0, 133.2, 145.7, 147.3, 
148.3, 149.7, 167.3; MS (ES): m/z 322 (M+H+).  
In procedure b, berberine chloride was irradiate at 250 W, 200°C for 10-15 min, 
washed with ethanol and filtered (yield 62%)14.  
 
1H-NMR (DMSO-d6, 400 MHz): δ 3.25 (t, 2H, J= 6 Hz), 4.10 (s, 3H), 4.96 (t, 2H, J= 6 Hz), 
6.23 (s, 2H), 7.12 (s, 1H), 7.76 (d, 1H, J= 8 Hz), 7.84 (s, 1H), 8.15 (d, 1H, J= 8 Hz), 8.89 (s, 
1H), 9.97 (s, 1H), 11.32 (br s, 1H). 13C-NMR (DMSO-d6, 100 MHz): δ 26.5, 54.9, 57.1, 
102.0, 105.4, 108.4, 117.6, 118.1, 119.8, 120.7, 125.5, 130.5, 132.4, 136.6, 143.7, 
145.4, 145.8, 147.7, 149.6. 
 
  
Figure 3. Synthesis of berberubine (M1) 
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Demethylenberberine  
The semi-synthesis of demethylenberberine through the hydrolysis reaction of the 
berberine chloride acetal ring, in the presence of sulfuric acid and phloroglucin, was 
reported in  
 
Figure 4.   
 
 
 
 
 
Figure 4. Synthesis of demethyleneberberine (M3) 
 
1H-NMR (DMSO-d6, 400 MHz):  3.18 (t, 2H, J= 6.0 Hz), 4.12 (s, 3H), 4.15 (s, 3H), 4.96 (t, 
2H, J= 6.0 Hz), 6.91 (s, 1H), 7.60 (s, 1H), 8.11 (d, 1H, J= 8 Hz), 8.23 (d, 1H, J= 8 Hz), 8.82 
(s, 1H), 9.45 (br s, 1H), 9.89 (s, 1H), 10.23 (br s, 1H). 13C-NMR (DMSO-d6, 100 MHz): 
25.8, 55.6, 57.1, 61.9, 112.7, 114.9, 117.8, 119.3, 121.2, 123.5, 126.7, 127.2, 133.3, 
138.3, 143.5, 145.1, 145.6, 149.2, 150. MS (ES): m/z 324 (M+H+). 
 
 
1.1.4.3 Liquid chromatography and mass spectrometry 
The HPLC system used is a 2690 Alliance system (Waters, Milford, MA, USA) combined 
with a triple quadruple mass spectrometer QUATTRO-LC (Micromass; Waters) using an 
electrospray interface (ES). Analytical separation was achieved using a Phenomenex 
Luna C18 (5 µm, 150 mm × 2.0 mm i.d.) column. 
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1.1.4.3.1 HPLC optimization 
The mobile phase used to achieve a good separation between berberine and its 
metabolites was 10 mM formic acid in water adjusted to pH 4.0 with ammonia (solvent 
A) and a solution of acetonitrile: methanol = 95:5 v/v (solvent B) using a gradient 
elution (5 min at 95% A and 10 min at 40% A, 5 min at 20% A, 10 min at 0% A) at 0.15 
mL min−1 flow rate. The analytical column was maintained at 30°C and the sample 
volume injected was 10 µL.  
In the optimized analytical conditions, the mean retention times were for BBR 10.0 ± 
0.2 min, M1 10.4 ± 0.2 min, M3 9.2 ± 0.2 min, and M4 9.8 ± 0.2 min (n = 20). The 
reconstruction ion chromatogram (RIC) for BBR and its metabolites is reported in 
Figure 5.  
 
Figure 5. Reconstructed ion chromatogram of BBR, M1, M3 and M4. 
 
1.1.4.3.2 ES mass spectrometry optimization 
The HPLC was coupled to a electrospray source (ES) operating in positive ion mode, 
connected to a triple-quadruple mass spectrometer. For each analyte a standard 
solution (0.1 g/mL in 10 mM formic acid (pH 4.00): methanol 50:50 (v/v), flow of 20 L 
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min-1) was directly infused into the mass spectrometer to find the optimal tuning 
parameters, reported in  
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Table 1.   
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Table 1. Tuning parameters BBR and its metabolites  
Instrumental parameters  BBR M1 M3 M4 IS 
Ionization mode + + + + + 
Capillary voltage (kV) 3.3 3.3 3.3 3.3 3.3 
Cone voltage (V) 44 47 44 43 42 
Source temperature (°C) 130 130 130 130 130 
Desolvation temperature (°C) 410 410 410 410 410 
Nebulizer rate (L/h) 65 65 65 65 65 
Desolvation rate (L/h) 1065 1065 1065 1065 1065 
RCE (%) a 30 30 30 30 30 
Collision gas Ar Ar Ar Ar Ar 
Parent ion (m/z) 336 322 324 338 414 
Daughter ion (m/z) 320 307 280 323 220 
 
a 
Relative collision energy 
 
Detection was performed by Multiple Reaction Monitoring (MRM) operating in the 
positive ionization mode, by monitoring the transitions at m/z 336→ 320 BBR), m/z 
322→ 307 (M1), m/z 324→ 280 (M3), m/z 338→ 323 (M4), and m/z 414→ 220 ((R,S)-
noscapine).  
21 
 
 
Figure 6. Mass spectra of berberine and its fragmentation scheme 
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1.1.4.3.3 Method validation 
The developed HPLC-ES-MS/MS method was validated according to the current 
guidelines15 used in drug analysis. The required validation parameters, i.e., specificity, 
limit of detection and quantification, linearity range, accuracy and precision are 
reported below.  
 
Specificity 
The HPLC-ES-MS/MS method developed presents a high specificity because 
compounds of closely related structures, as BBR and its metabolites are discriminate 
by different retention times and mass spectra. 
 
Limit of detection and quantitation  
Limits of detection (LOD), estimated as the signal-to-noise ratio (S/N) equal to 3, was 
0.08 ng/mL for each analyte. The limit of quantification (LOQ), estimated as S/N equal 
to 9, is 0.5 ng/mL for each analyte.  
 
Linearity range 
Linearity was studied in the range from 0.5 to 20 ng/mL for each analyte.  
Linear calibration curve parameters were obtained from the plot of the analyte peak 
area/internal standard peak area versus analyte concentration using a least squares 
regression analysis (weight = 1/x2). Plasma calibration curve of BBR and its metabolites, 
expressed as y= (a ± DS)+ (b ± DS)x, was reported in Table 2. The performance of the 
analytical method was monitored using three quality control samples (QCs) having 4.5 
nM for QC low, 20 nM for QC med and 45 nM for QC high.  
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Table 2. Calibration curves of BBR and its metabolites in plasma 
  
Analytes y= (a ± DS)+ (b ± DS)x R2 
BBR y= (-0.0133 ± 0.0001) + (0.339 ± 0.055)x  0.993 ± 0.005 
M1 y= (-0.050 ± 0.004) + (0.809 ± 0.055)x  0.990 ± 0.003 
M3 y= (-0.018 ± 0.005) + (0.159 ± 0.024)x 0.991±0.001 
M4 y= (-0.0014 ± 0.0008) + (0.095 ± 0.051)x 0.994±0.001 
 
a= intercept; b=slope; x= concentration (ng/mL); DS=standard deviation; R
2
= coefficient of determination 
 
Accuracy and precision 
Accuracy (bias %) and precision (coefficient of variation, CV %) were determined intra-
day, evaluated during the same day, and inter-day, evaluated during three days, using 
the triplicate analysis of the QCs for each analyte ( 
Table 3).  
 
Table 3. Accuracy (bias %) and precision (CV %) of BBR and its metabolites 
Accuracy and precision 
 BBR M1 M3 M4 
 C (nM) CV% bias% CV% bias% CV% bias% CV% bias% 
In
tr
a-
d
ay
 
4.5 (QC low) 9 7 7 2 8 1 7 7 
20 (QC med) 2 3 2 1 8 1 4 1 
45 (QC high) 1 1 3 2 5 2 3 4 
In
te
r-
d
ay
 
4.5 (QC low) 7 5 7 1 7 7 11 5 
20 (QC med) 5 1 4 1 4 1 3 1 
45 (QC high) 2 3 1 3 3 2 1 3 
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Recovery and matrix effect 
The extraction efficiency of solid phase extraction was expressed as recovery. The 
recovery % was > 90 % for each analyte while the matrix effect was < 10%. 
 
 
1.1.4.4 Physicochemical properties 
Determination of pKa values 
The pKa values were determined in silico using Epik module version 2.2 from 
Schrödinger Suite 2010, setting water as solvent and using the maestro interface of 
Schrödinger Suite 2010 (Maestro, version 9.1, Schrödinger, LLC, New York, NY, 2010) to 
build all molecules. 
 
Determination of water solubility  
The solubility was experimentally determinated in Na phosphate buffer 0.1 M from pH 
4.5 to 9 for each analyte under continuous stirring at 25 °C, for 1 week. Then, each 
solution was filtrated on RC membrane 0.45 µm syringe filters and injected in HPLC-ES-
MS/MS after an appropriate dilution with mobile phase. 
   
Determination of 1-octanol/water partition coefficient  
The determination of 1-octanol/water partition coefficient was experimentally 
determinated in Na phosphate buffer from pH 4.5 to 9.0 for each analyte. Briefly, for 
each analyte 2mL of a standard solution (0.1 mM) in Na phosphate buffer, 
presaturated with 1-octanol, was added to 2 mL of 1-octanol (presaturated with Na 
phosphate buffer). The system was left to equilibrate for 1 week under continuous 
stirring at 25 °C. Then, the two phases were carefully separated by centrifugation. The 
aqueous solution was appropriately diluted with mobile phase and injected in HPLC-
ES-MS/MS.  
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Determination of albumin binding association constants  
The determination of  albumin binding association constants (KB) were performed 
using bovine serum albumin (BSA) 10 µmol L-1 in Tris-HCl buffer solution (0.05 mol L-1 
Tris, 0.15 mol L-1 NaCl, pH 7.4) by fluorescence quenching. The emission spectra was 
obtained recording the increasing concentrations of quencher (Q: BBR, M1, M3, M4) 
from 0 to 24 µmol L-1 (increments of 2 µmol L-1) setting the excitation at 295 nm and 
emission wavelengths of 300-500 nm.  
The experimental results published on BBR quenching mechanism of fluorescence of 
indicate that it’s a static quenching procedure16. For this reason, the binding 
association was determinated by plotting modified Stern-Volmer equation (Figure 7).   
 
Figure 7. BSA emission spectra in presence of quencher (left) and modified Stern-
Volmer plot (right) 
 
where: 
F0 – fluorescence intensity in absence of quencher 
ΔF – difference in fluorescence in absence and presence of quencher 
fa  – fraction of accessible fluorescence 
KB – effective quenching constant for the accessible fluorophores 
Q – concentration of quencher 
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1.1.4.5 Pharmacokinetics and bioavailability of berberine in 
human  
The same formulation of Berberis Vulgaris enriched extract (250 mg cps) was acutely 
and chronically administered to human subjects in order to better understand 
berberine pharmacokinetics and the biodistribution. 
The pharmacokinetics study was carried out by administering 500 mg of berberine to 
healthy subjects (n=10). Plasma samples were collected at different times after 1, 2, 3, 
4, 6, 8, 24 h respectively.  
Concerning the subchronic bioavailability study, hypercolesterolemic patients (n=12) 
received 15 mg/kg daily of berberine for three months (from a minor daily dose of 3 
cps/day to a maximum daily dose prescribed 6 cps/day). Patient inclusion criteria were 
as follows: age 18 – 70 year-old; c-LDL>130 mg/mL and <190 mg/mL; fasting 
glucose<100 mg/mL. Total cholesterol, c-LDL, c-HDL, triglycerides, was evaluated 
before enrollment (V0) end after three month of berberine chloride chronically 
administered (V3) to evaluate the hypolipidemic effect of berberine.  
These studies have been approved by the Ethical committee of the S.Orsola University 
Hospital (Review Board No. 7-2209-U-SPER). 
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1.1.5 Results and discussion 
1.1.5.1 Physicochemical properties 
The physicochemical properties of berberine and its metabolites, including pKa, 
solubility, lipophilicity and albumin binding, are reported in Table 4. 
 
pKa 
In silico, the pKa prediction is possible only for molecule containing proton donor or 
acceptor groups. For this reason the determination of pKa was performed only for 
berberine metabolites and no for berberine, assuming that its iminium cation would 
remain as such in all pH range. 
The simultaneous presence of the iminium cation and the hydroxyl group in the 
structures of berberine metabolites play a crucial role. Indeed, these compounds could 
take on the characteristics of neutral molecules when pH is higher than the pKa value. 
Specifically, M3 and M4 are partially dissociated in physiological pH, having a pKa value 
9.4 and 9.6 respectively. No pKa value was retuned for M1 as the most stable tautomer 
in water was its neutral quinoid form.   
In order to demonstrate the keto-enolic equilibrium of M1 (Figure 8), its quinoid form 
was synthetized and an NMR study was performed.   
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Water solubility 
As show in Table 4, the solubility of berberine was not influenced by pH variation while 
the solubility of M3 and M4 increased significantly when pH was increased. Concerning 
M1, its solubility decreased when pH was increased and the color of M1 in solution 
turned from yellow at acidic pH to red a basic pH. This bathocromic effect could be due 
to prevalence of enolic form at low pH and quinoid form M1-keto at high pH, as 
previously hypothesized.  
 
  
Figure 8. Keto-enolic equilibrium of M1 
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Lipophilicity 
The coefficient partition 1-octanol/water (LogPo/w) of berberine and its metabolites 
are reported in Table 4.  
Unlike its metabolites, the LogPo/w of BBR is not greatly influenced by pH because in 
its structure there are not proton donor or acceptor functional groups. Thus the only 
species present in its solution, at each pH value, is BBR as such (Figure 1).  
BBR, M3 and M4 could be classified as hydrophilic compounds (LogPo/w<0) while 
conflicting data are obtained for M1. 
The lipophilicity of M1 is strongly influenced by pH variation, increasing with increasing 
pH from Log -0.02 to 1.6. This latter value is in disagreement with its nominal enolic 
structure indeed M1 should be more hydrophilic than berberine. This M1lipophilicity 
variation could be attributed to the predominance of the enol form (total positive 
charge) at acid pH (4.5) and the quinoid form at basic pH (total neutral charge), that is 
more liposoluble. Indeed, as seen in solubility assay, a different phase color was 
observed during the partition in 1-octanol and aqueous medium of M1: yellow in 
aqueous phase and red in 1-octanol (Figure 9).  
Figure 9. Coefficient partition 1-octanol/water of M1 
 
Albumin Binding 
In Figure 10 the tryptophan fluorescence quenching effects induced by berberine, M1, 
M3 and M4 respectively are reported. The presence of a double peak in quenching 
profile of BBR, M3 and M4, suggest that they bind both binding sites of BSA. On the 
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other hand, the quenching profile of M1 is characterized by a single peak suggesting 
that this metabolite bind only one sites of BSA. The affinity constants binding are 
reported in Table 4. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Emission spectra of BSA (0.1 µM) at different concentrations of: (A) BBR, (B) 
M1, (C) M3, and (D) M4 (λext = 280 nm) 
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Table 4. Physicochemical properties of BBR and its metabolites 
Compound 
pHa 
gradient 
Solubility 
(mM) 
LogPo/wa LogDo/w 
KB
b 
(x103 L·mol-1) ± SD 
BBR 
8.6 9.6 -1.2 -1.2  
7.0 9.0 -1.2 -1.2 3.37 ± 0.09 
6.0 7.6 -1.2 -1.2  
4.5 8.2 -1.2 -1.2  
in silico - -0.4 -  
M1 
8.6 0.5 1.6 4.6  
7.0 1 1.1 2.5 1.51 ± 0.03 
6.0 2 0.9 1.4  
4.5 4.2 -0.02 0.01  
in silico - 1.0 -  
M3 
8.6 6.5 -0.5 -0.3  
7.0 3.7 -1.1 -1.1 1.98 ± 0.09 
6.0 0.2 -1.1 -1.1  
4.5 0.2 -1.1 -1.1  
in silico - 0.1 -  
M4 
8.6 12.2 0.1 0.6  
7.0 12.4 -1.2 -1.2 1.73 ± 0.01 
6.0 1.3 -1.5 -1.5  
4.5 1.5 -1.5 -1.5  
a
phosphate buffer 0.1 M. 
b
at 298 K in 0.1M Tris-HCl pH = 7.2 (n.d.= not determined). 
c
Chloride salt 
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1.1.5.2 NMR characterization of berberrubine 
In order to demonstrate the keto-enolic equilibrium of M1, NMR spectroscopic studies 
have been performed. In particular, the NMR characterization was carried out for a 
equimolar mixture of enol and quinoid form of M1, using several NMR spectroscopic 
technique. Specifically, the 1H-NMR spectra of this equimolar mixture displayed only 
one average set of signals, confirming that a fast equilibrium between this two 
tautomeric forms take place. 
In addition, a 1H-15N HMQC (recorded at 40° C in DMSO-d6) correlation analysis was 
carried out for both structures. In the NMR of enol form, correlations of H8 triplet and 
the H11 singlet with N10 resonance at 193 ppm were observed. As expected, the same 
correlations (Figure 11) of H8 triplet and the H11 singlet with N10 were obviously 
observed for quinoid form while N10 resonance was found at 164 ppm. The difference 
between the chemical shifts for the two 15N resonances is due to the different electron 
density of quaternary N atom in enol form and that of tertiary N atom in quinoid form.  
 
 
Figure 11. 1H-15N HMQC correlations for the enol form and quinoid form 
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1.1.5.3 Plasma sample extraction and clean up  
Analytes were extracted from plasma using an Oasis HLB (hydrophilic−lipophilic 
balance 200 mg, 6 mL) SPE column. The optimized extraction procedure utilized: 
conditioning with 2 mL of MeOH and 2 mL of H2O Milli-Q; loading with 100 µL of 
plasma (+10 µL of IS, 10 ng/mL) diluted with 2 mL of ammonium formiate (10 mM pH 
7.0), washing with 1 mL of formic acid (2%, v/v) and 2 mL of ammonium formiate (10 
mM pH 7.0), elution with 2 mL of MeOH, followed by 1 mL of MeOH containing 1% 
(v/v) CH3COOH and 1 mL of MeOH containing 2% (v/v) NH4OH, vacuum drying, and 
reconstitution with 100 µL of mobile phase. The recovery percentage was ≥90% for all 
analytes. 
 
1.1.5.4 Pharmacokinetics and bioavailability of berberine in 
human 
In Figure 12 are reported plasma levels of BBR and its metabolites after acute and 
chronic administration.  
Concerning the pharmacokinetic study, the curve of BBR, M3 and M4 are quite similar. 
Their maximum plasma concentration are very low, i.e. 0.07 ± 0.01 nM for BBR, 0.14 ± 
0.01 nM for M3, and 0.13 ± 0.02 nM for M3. Instead, plasma levels of M1 reach a 
maximum concentration of 1.4 ± 0.3 nM, ten times higher than BBR and others 
metabolites.  
After chronic administration (Figure 12), a bioaccumulation of BBR and its metabolites 
was observed. The steady-state levels were 4.0 ± 2.0 nM, 6.7 ± 3.0 nM, 1.7 ± 0.3 nM, 
and 5.6 ± 2.0 nM for BBR, M1, M3 and M4 respectively.   
These plasma levels are higher than those after acute administration because the dose 
was twice compared to acute one.   
In  
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Table 5 the comparison of cholesterol (total, LDL and HDL) and total triglycerides 
before (V0) and after the treatment with Berberine chloride for three months (V3) was 
reported. 
Among biochemical-marker of hypercholesterolemia, a significant reductions in total 
and LDL cholesterol (p<0.05 obtained by the paired two-tailed Student’s t test) was 
observed and this is in agreement with previously published data17. In contrast, total 
triglyceride and cholesterol-HDL levels were not significantly different (p>0.05) before 
and after chronic administration of BBR. 
 
 
Figure 12. Plasma levels of BBR, M1, M3 and M4 (A) acute administration of BBR 500 
mg (n=10) (B) chronic administration of of BBR 15 mg/kg  
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Table 5. Biomarkers of hypercholesterolemia before (V0) and after the treatment with 
Berberine chloride (V3) 
 
Patient total-cholesterol 
(mg/dL) 
LDL  
(mg/dL) 
HDL  
(mg/dL) 
triglycerides 
(mg/dL) 
 V0 V3 V0 V3 V0 V3 V0 V3 
1 268 233 173 138 65 59 134 179 
2 238 251 162 181 50 51 119 87 
3 193 205 133 138 35 36 113 156 
4 196 147 131 90 51 46 63 48 
5 211 187 136 115 45 43 133 132 
6 211 200 132 111 69 70 47 87 
7 201 188 126 111 48 51 120 118 
8 241 227 174 158 39 37 126 162 
9 276 267 194 197 48 46 168 110 
10 229 226 145 141 56 58 128 123 
11 213 182 137 124 38 37 190 95 
12 225 210 149 137 49 49 122 118 
P 0.016* 0.025* 0.312 0.753 
p= paired two-tailed Student’s t test 
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1.1.5.5 Correlation between plasma levels and physicochemical 
properties  
Among the physicochemical properties studied for BBR and its metabolites, the pKa 
and the lipophilicity are correlated with plasma levels after oral administration. As 
previously reported, pKa values showed that BBR, M3, and M4 were permanently 
charged at the physiological pH range while M1 tautomerized in its neutral quinoid 
form (Figure 13). 
This keto-enol tautomeric equilibrium was strongly influenced by pH and the two 
forms of M1 (i.e. enol and quinoid form) interconvert rapidly into each other. Likely, 
the prevalence of its enolic form or quinoid form was continuously modulated in vivo 
and their separation could be promoted by a membrane in systemic compartment. The 
intestinal adsorption of quinoid form could be more efficient than enol form because a 
neutral molecule cross much better membranes than a charged one (Figure 13). 
 
 
Figure 13. pH-mediated passive diffusion of M1 through the cell membrane 
 
Summarizing, BBR has an unusual metabolism through it produces a metabolite, M1, 
more lipophilic than BBR in its quinoid form. For this reason, it was hypothesized that 
M1 could be adsorbed by passive diffusion and this accounts for its higher plasma 
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levels. Thus M1 accumulates in systemic compartment more than BBR and other 
metabolites and as discussed above, M1 seems to be more pharmacologically active 
but this hypothesis should be demonstrated by the direct administration of M1. 
 
 
1.2 Berberrubine 
1.2.1 Pharmacological and therapeutic effects 
As reported above, M1 showed a cholesterol-lowering efficacy, although its activity 
was lower than BBR (about 40% lower). In order to improve the low bioavailability of 
BBR, several prodrugs of M1 were designed, in which the 9-hydroxl group of M1 was 
replaced with different ester groups. Consequently its cholesterol-lowering effect is 
increased because these new compounds are more lipophilic than M1 and BBR18.  
In addition, recent studies have been demonstrated that berberrubine exhibits anti-
tumor activity in animal models. In particular, M1 exhibits an antitumor activity higher 
than BBR, due to the hydroxyl group at the 9-position in the M1 structure. The 
substitution of the methoxy group in BBR structure with an hydroxyl group in M1 could 
mediate DNA cleavage by topoisomerase II19,20.  
 
 
1.2.2 Aim and rationale 
Despite its significant pharmacological effect, the bioavailability of BBR (Figure 1), 
obtained by the area under the curve and maximum concentration in blood, was less 
than 1%. BBR is an isoquinoline alkaloid isolated from several Chinese herbal 
medicines, such as Coptis chinensis, Berberis aristata, and Coptis japonica that exhibits 
a multi-taget activity. In particular a lipid-lowering effect by up-regulating the hepatic 
low density lipoprotein receptor (LDLR) expression is obtained after oral 
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administration of 500mg/die of berberine chloride. As well as BBR, also its primary 
metabolites showed a cholesterol-lowering effect although less than BBR activity.  
Recently, several studies21 have been carried out to explain how this molecule so 
poorly bioavailable exhibits these important pharmacological activities. In particular, 
the biodistribution of BBR and its metabolites in main organs or tissues was further 
investigated. After oral administration a dominant tissue distribution of BBR and its 
metabolites was observed in the liver. This pharmacological result has been used to 
explain why BBR is active in vivo, even if its blood concentration is low. Indeed, the 
authors have been hypothesized that an accumulation of BBR and its metabolites 
could explain their therapeutic effect on cholesterol, glucose and triglycerides in 
patients.  
Although the bioavailability of BBR is low, the concentration of M1 in blood was ten 
times higher than BBR and others metabolites (as reported below). For this reason M1 
could be potentially more pharmacologically active than berberine.  
Previously we have demonstrated that M1 could tautomerized in its quinoid form 
which could accumulate in systemic compartment more than BBR.  
In order to demonstrate the tautomeric equilibrium in vivo of M1, in vivo experiments 
on "rat with external biliary fistula" were carried out. Specifically, M1 will be duodenal 
administered at 10mg/kg. Plasma, liver and bile will be collected during all the 
experiment. Then, the biodistribution of M1 will be compared with BBR.  
For this purpose it will be necessary to develop and validate clean up procedures for 
the extraction and purification of analytes by these matrices.  
 
1.2.3 Experimental 
1.2.3.1 Materials and reagents 
Wistar-Han rats (male, 180–220 g, 6–7 weeks) for the following pharmacokinetic study 
were obtained from Charles River Laboratories, Carlo, Italy. All the experiments were 
conducted following relevant National and International Guidelines according to Public 
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Health Service Policy on Humane. The animals were maintained on a 12-h light/dark 
cycle (light on from 8:00 AM to 8:00 PM) at ambient temperature (22–24 °C) with 45% 
relative humidity. The rats were fasted for 12 h before all experimental studies.  
 
1.2.3.2 Comparison between pharmacokinetics and 
biodistribution of berberine and berberrubine in bile fistula rat 
animal model 
The animal model used was the bile fistula rat in which, the bile duct was cannulated 
to collect the bile at time interval after intraduodenal administration of the compound 
per gavage. Berberine and M1 were infused at a dose of 500 nmol/kg/min (10mg/kg) 
over 2 hour at 2.5 ml/hour.  
Bile was collected at 15 minutes time intervals throughout the infusion and over 2 
hours after the infusion was over while plasma was collected every 30 minutes and 
liver at the end of experiment. The bile flow was evaluated gravimetrically by the 
volume of bile recovered at the different time-intervals, while the concentration of the 
administered compounds and its main metabolites were measured in bile, plasma and 
liver samples with the HPLC-ES-MS/MS as reported below.  
In the anesthetized animal, the intestinal motility is hampered not allowing the 
progression of the substance.  For this reason an intraduodenal infusion was preferred 
over the single bolus infusion in which the absorption would be disturbed by the 
absence of luminal stirring. 
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1.2.4 Results and discussion 
1.2.4.1 Sample extraction and clean-up procedures: bile and 
liver  
Bile Sample Preparation 
Rat bile samples were brought to 25°C and diluted 1:10000 v/v with ammonium 
formiate buffer 10 mM pH 4.0 and acetonitrile−methanol (95:5 v/v) in ratio 95:5 (v/v) 
and 5 µl was injected in HPLC-ES-MS/MS system.  
 
Liver Sample Preparation 
Aliquots weighing approximately 1 g each were taken from different points of the liver 
sample. Each aliquot was weighed, and 2 ml of phosphate buffer (0.005 M, pH 7.2) was 
added. The mixture was homogenized using a potter, which was then washed with 3 
mL of methanol. The liver extract was sonicated for 5 minutes, vortexed for 2 minutes, 
heated to 37°C for 20 minutes, and centrifuged at 2100g for 15 minutes. Four hundred 
microliter of the supernatant was spiked with 10 µl of the internal standard working 
solution and dried under vacuum. The residue then was re-suspended with 2 ml of 
ammonium formiate (10 mM pH 7.0) and SPE was carried out on HLB extraction 
cartridges (as shown above). The eluate was dried under vacuum and reconstituted 
with 200 ml of the mobile phase) and injected into the HPLC-ES-MS system. 
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1.2.4.2 Metabolism of berberrubine 
The metabolism of berberine has been further investigated, and M1, M2, M3 and M4 
were identified as main primary metabolites (Figure 1).  
In this work, it was hypothesized that, as well as berberine, M1 might be further 
metabolized in the liver by CYP450 isoenzymes through oxidative demethylation at 
positions 2, 3, 9, and 10 followed by conjugation of these hydroxyl group functions 
with glucuronic acid. The hypothesized primary metabolites of M1 were reported in 
Figure 14.  
 
  
Figure 14. Primary metabolism of M1 
42 
 
1.2.4.3 Comparison between pharmacokinetics and 
biodistribution of berberine and berberrubine 
The bile flow and bile secretion of M1 (A) and BBR (B) are reported in Figure 15 and 
Figure 16. After duodenal infusion of M1 and BBR, a reduction of bile flow was 
observed for each compound, reaching a minimum volume secretion (SVmin) of 20 
and 2.9 µL/min/kg for M1 and BBR respectively. The bile flow reduction could be due 
to the animal model chosen in which the enterohepatic circulation was interrupted.  
 
Figure 15. Bile flow of A) M1 and B)BBR 
 
Concerning their biliary secretion, it is more efficient for M1 than BBR. Indeed, the 
maximum bile secretion (SBmax) of M1 is 6 times higher than BBR SBmax (i.e. 19.6 and 
3.3 nmol/ min/ kg). In bile M1 was poorly metabolized to mono and dihydroxyl 
derivatives while BBR was metabolized in M1, M3 and M4 (SBmax i.e. 1.3, 1.2 and 
1.2.nmol/ min /kg).   
43 
 
 
 
 
Plasma profiles of M1 and BBR were reported in Figure 17. As expected, the 
bioavailability of BBR is very low, reaching a maximum plasma concentration (Cmax) of 
0.046 µM after 240 min. In particular, after duodenal infusion of BBR, it is mainly 
metabolized to M1 (Cmax 0.085 µM after 120 min) and less to M3 and M4 (i.e. 0.05 
and 0.025 µM). Differently from BBR after duodenal infusion, M1 was poorly 
metabolized reaching a Cmax of 11.8 µM after 240 min.  
 
Figure 17. Plasma levels of A) M1 and B) BBR 
 
In liver, the amount of M1 was 52 nmol/g after its direct administration and no 
metabolites were detected. Unlike, after duodenal infusion of BBR, the amount of BBR 
Figure 16. Bile secretion of A) M1 and B) BBR 
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was 34.4 nmol/g, 26.5 nmol/g for M1, 1.6 nmol/g for M3 and 8.4 nmol/g for M4 
respectively.  
 
1.3 Conclusions 
The physiochemical properties of BBR and of its metabolites showed that it has an 
unusual metabolism as its metabolite M1 is more lipophilic than BBR. Indeed the 
nitrogen atom of M1 structure could be tetravalent with a positive charge in its enol 
form and trivalent and electroneutral in quinoid form (Figure 13) by keto-enol 
tautomerism equilibrium unlike BBR and the other metabolites. It was hypothesized 
that the intestinal adsorption of M1 quinoid form could be more efficient than enol 
form because a neutral molecule cross better membranes than a charged one. In this 
way, M1 could be adsorbed by passive diffusion and be pharmacologically more active 
than BBR.    
Indeed, the direct administration of M1 has shown that it is more efficiently secreted 
in bile than BBR with a SBmax of 19.6 and 3.3 nmol/min/kg respectively. In addition, 
the metabolism of M1 was widely investigated. Although, M1 was poorly metabolized 
unlike as observed for BBR in which the SBmax of its metabolites was 1.3, 1.2 and 1.2 
nmol/min/kg for M1, M3 and M4 respectively. The main metabolites present in bile 
were 3-hydroxy, 10-hydroxy, 2,3-dihydroxy and 2,10-dihydroxy derivatives reaching a 
SBmax of 2.82, 1.87, 0.47 and 0.98 nmol/min/kg respectively.    
Concerning plasma levels, M1 exhibited a higher concentration both when it was 
directly infused (Cmax=11.8 µM) and when it was produced by BBR (Cmax=0.085 µM, 
time 120 min) compared to BBR plasma levels as expected.  In particular, unlike BBR 
(Cmax=0.046 µM), M1 was detected as such in plasma and poorly metabolized. In the 
liver, M1 was detected as such (52 nmol/g) and no metabolites were detected. After 
duodenal infusion of BBR, the same total amount reaching for M1 was observed (BBR 
was 34.4 nmol/g, M1 26.5 nmol/g, M3 1.6 nmol/g and M4 8.4 nmol/g).  
Based on this consideration, M1 could be highly conserved in enterohepatic circulation 
(Figure 18) thought to be actively absorbed in the ileum in its quinoid form by keto-
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enol tautomerism. Indeed, in the intestine (pH>6.00) the neutral quinoid form of M1 is 
the most abundant species. Then the quinoid form of M1 could be reabsorbed by 
active transport at end of small intestine resulting in a higher concentration in blood.  
Studies on the relationship with biomarkers of different diseases are currently 
underway for M1 in enol and quinoid form.  
The overall data suggest the importance of accurate preclinical studies of natural 
products. In particular studies on biodistribution, metabolism, and accumulation in 
target organs should be carried out although not required by the regulatory 
authorities. Moreover the metabolism and biodistribution are strongly influenced by 
administered dose. A lack of this information represents a serious risk for the 
consumers’ safety. In addition, in order to improve the lead discovery for 
pharmaceutical research based on natural sources, a physicochemical characterization 
should be carried out. In this physicochemical characterization the major metabolites 
of biologically active compound should be included.  
 
Figure 18. Enterohepatic circulation of M1 
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Chapter 2 
Functional foods: glucosinolates  
In the nutraceutical definition, functional foods are included since they are foods 
fortified with one or more biologically active molecules, providing a health benefit 
beyond basic nutrition. The depth study of foods chemical composition, such as fruits 
and vegetables, is a deal of great actuality for prevention, as it may lead to the 
discovery of new functional foods without any added cost22.  
For disease prevention, an optimization of composition of vegetables and fruits would 
be very cost-effective. Recognized candidates as potentially health promoting 
compounds, and ones which are currently under investigation in many research 
projects include organosulphur compounds.  
The research on functional foods has focused on broccoli and on a single bioactive 
component within broccoli, sulphoraphane. Indeed, active components present in 
these vegetables, as isothiocyanates and indole-3-carbinol, showed an 
anticarcinogenic action has been extensively studied in experimental in vivo22. 
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2.1 Glucosinolates 
2.1.1 Structure and properties 
Glucosinolates (GLS) are naturally occurring polar molecules classifiable as (Z) β-
thioglucosides N-hydroxysulfate endowed with a lateral chain (R) and a β-D-
glucopyranosil moiety linked to S-atom (Figure 19). GLS are produced by over sixteen 
plant species as Brassicaceae, Capparaceae e Caricaceae (broccoli, rocket salad, 
cabbage and mustard)22. In particular, GLS are the main responsible of organolectic 
properties of these vegetables.  
 
 
 
Figure 19. Structure of glucosinolates 
 
GLS are hygroscopic, highly hydrophilic compounds having a 1octanol-water partition 
coefficients ranging from -1 to -3. They have a good thermostability (stable up to 110 
°C in their purified form, while even more stable if in their natural matrix) and occur in 
nature as extremely water soluble anions. Because of the sulfate group acidity, 
glucosinolates are concentrated in plant vacuoles as potassium salts.  
They could be classified by the chemical structure of their lateral chain in aliphatic, ω-
metilthioalchylic (alifatic glucosinolates), aromatic or etherocyclic (aromatic 
glucosinolates) chains. Among them, many glucosinolates present linear or branched 
lateral chains, double bonds, carbonyl groups, hydroxyl groups and thio-groups in 
different oxidation states. 
Glucosinolates total content in leaves is about 1% of the dry weight but its amount 
reaches 10% in some seeds23. Glucosinolates are biosynthesized starting from glucose 
and aminoacids23. Briefly, their biosynthesis is composed by three steps24: lateral chain 
elongation, glucone synthesis and structural modifications of the lateral chain. 
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Elongation proceeds thanks to specific genes. Once completed lateral chain elongation, 
biosynthesis proceeds with the N-oxydrilation, followed by decarboxylation to form an 
aldoxime. Such aldoxime is oxydized to tiohyroxamic acid, which is glycosylated on the 
S-atom obtaining a desulphoglucosinolate. Finally the desulphoglucosinolate is 
converted to glucosinolate thanks to the addition of a sulphate group by the action of 
the enzyme desulphoglucosinolate sulphatetrasferase (PAPS). Reactions modifying 
aminoacid lateral chain are mainly oxidation reactions on the S-atom, alchilic portions 
desaturation and double bond hydration. 
 
2.1.2  Glucosinolates metabolism: isothiocyanates   
Glucosinolates are hydrolyzed by myrosinase enzyme to produce a wide range of 
degradation products with different biological activities. Indeed, myrosinase is an 
endogenous thioglucohydrolase enzyme present in plants that cleaves off the glucose 
group from a glucosinolate with the production of thiohydroxammate O-sulphonate 
derivative. This intermediate decompose to several hydrolysis products: 
isothiocyanates (ITCs), thiocyanates, nitriles, epithionitriles, oxazolid-2-thiones and 
indolyl compounds (Figure 20). Among the degradation products of GLS, ITCs show the 
most important biological activity and nutraceutical applications, as reported above.   
 
 
 
 
 
 
 
  Figure 20. Glucosinolates hydrolysis 
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2.1.3 Biological activity and nutraceutical applications 
The epidemiological evidence for cancer protection25 associated with consumption of 
Brassica vegetables is attributed to the glucosinolates. However, cancer cell toxicity 
experiments have demonstrated that GLSs are not bioactive25. In contrast, their 
degradation products, isothiocyanates (ITCs), show important biological activity. In 
particular they are able to influence phase I and phase 2 biotransformation enzyme, 
thereby possibly influencing several processes related to chemical carcinogenesis, e.g. 
the metabolism, DNA-binding and mutagenic activity of promutagens25. Their 
anticarcinogenic action depends on many factors, such as the test system, the target 
tissue, the type of carcinogen challenge and the anticarcinogenic compound, their 
dosage, as well as the timing of the treatment.  
In addition, ITCs showed an antinflammatory, bactericide26, fungicide27 and 
nematocide28 activity. 
By far the major ITCs well studied are erucin, sulforaphane, allilisothiocyanate, 
phenetilisothiocyanate and indole-3-carbinol ( 
Figure 21) which derive, respectively, from glucoerucine, glucoraphanin, sinigrin, 
gluconasturtiin and glucobrassicin.  
On the other hand, negative effects of glucosinolates on animals are related to its 
concentration in diet. In particular, thiocyanates, thiourea and oxazolidithione may 
disrupt iodine availability to thyroid thus affecting thyroid function29. Other adverse 
effects of glucosinolate metabolites are goitrogenecity30,31,32, mutagenecity, 
hepatotoxicity and nephrotoxicity33,34. The negative influence of dietary glucosinolate 
on animal growth and production may be related to the drastic endocrine disturbance 
induced by antinutritional factor35. The reduced intake of GLSs containing diets is due 
to the presence of sinigrin and progoitrin, these both glucosinolates are associated 
with bitter taste36. 
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Figure 21. Glucosinolates metabolites best characterized 
 
 
2.1.4 Glucosinolates and isothiocyanates determination 
techniques 
Considering the great importance of glucosinolates, many extraction and quantitation 
methods have been developed.  
The current analytical method for the glucosinolates is the ISO 9167-1 protocol37 in 
which the glucosinolates are converted to desulphoglucosinolates (DS-GLS, Figure 22) 
using an enzymatic treatment “on column”. This reaction is performed into columns 
filled with anion exchange resin and conditioned using an acetate buffer. After 
conditioning a purified sulphatase and the extracts were loaded and left for 72 hours 
at room temperature allowing the reaction to complete. Then, desulphoglucosinolates 
are eluted with water, injected into HPLC column using a C18 as stationary phase and 
detected by UV. For the quantification, desulphobenzylglucosinolate as internal 
standard, desulphosinigrin as external standard and apposite correction factors for 
each analyte are used. The ISO protocol, however, is an indirect analysis method 
whose accuracy is strictly related to the conversion yield, it is quite slow; it has low 
sensitivity (0.1 µmol/mL) and low selectivity37. 
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Moreover little modifications to this protocol were done but the interlaboratories data 
often are in disagreement to each other. Although many HPLC-ESI-MS/MS methods 
were developed, the ISO protocol continues to be the most popular glucosinolates 
analysis method. Indeed, this method is fully validated and gives satisfying results 
(linearity range 0.1-3 µmol/mL; precision and accuracy 12% for both).  
The glucosinolates quantification was performed by GC in which GLSs were esterified 
by trimethylsilyl chloride, purified and injected into GC-column38 but this way totally 
replaced by the introduction of new HPLC methods of analysis.  
Different HPLC-ESI-MS/MS methods have been proposed, allowing new compounds 
discovery and the improvement of the chromatographic separations. Complex 
separations of many glucosinolates in vegetables matrices have been performed, up to 
12 analytes, with high selectivity and accuracy39. However, methods for the 
simultaneous quantification of glucosinolates and isothiocyanates were not developed 
to date. This may be due to their weak absorption at UV detectors and their bad 
ionization in negative mode into MS sources. However the development of an efficient 
sample extraction and clean-up and quantitative method applicable simultaneously to 
both GLSs and ITCs would be of high scientific and practice interest, as it may give the 
opportunity to monitor GLSs stability into functional foods in relation to their 
hydrolysis products. 
  
Figure 22. Glucosinolates conversion to desulphoglucosinolates 
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2.2 Aim and rationale 
Glucosinolates and their associated degradation products have been recognized long 
for their distinctive benefits to human nutrition and plant defense.  
Due to their beneficial effects, different functional foods were developed. Concerning 
GLSs, their stability during the whole industrial processing should be monitored to 
ensure the activity of functional foods, from cultivation to consumer processing40. In 
this way consumers will receive a functional food that is of higher nutritive quality and 
thus provides increased health benefits.   
It was demonstrated that some GSLs and their breakdown products are to be toxic, 
and even carcinogenic, at high concentrations41. Thus, an overconsumption of these 
compounds could have serious health consequences42 as high-dose−effect 
relationships are as yet unknown in humans43.   
The quantification of GLSs in functional foods is regulated by ISO 9167-1 procedure, 
based on their preliminary conversion into desulphoglucosinolates and a successive 
HPLC-UV quantitation, using desulphosinigrin as external standard and specific 
correction factors for each analyte. This method is based on indirect quantitation and 
accuracy is strictly related to the conversion yield. For a complete conversion, in fact, a 
reaction time of three days is required, so this kind of analysis is extremely long. 
Moreover UV detector is not very sensitive and selective and it could not provide an 
accurate quantification in less concentered samples. A direct, more robust and 
sensitive method could greatly optimize analysis time and could be applied into food 
industry for a quick and efficient quantification of these analytes into different 
matrices. 
The aim of this work is the development and validation of an HPLC-ESI-MS/MS method 
for the simultaneous separation and quantification of intact glucosinolates and 
isothiocyanates. This method will be applied to different matrices containing 
glucosinolates, in order to trace their profile.  
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2.3 Experimental 
2.3.1 Materials and reagents 
Glucoraphanin (GRA) and glucoerucin (GER) as standards and rocket salad seeds, 
broccoli and crackers extracts were supplied by Consiglio per la Ricerca e la 
Sperimentazione in Agricoltura, Centro di Ricerca per le Colture Industriali of Bologna 
(CRA-CIN). 
Sinigrin (SIN) standard was purchased from Sigma-Aldrich (Milano, Italy).  
Sulforaphane (SFN) and erucin (ERN) standards were purchased from Santa Cruz 
Biotecnology (Texas, U.S.A).  
 
2.3.2 Calibration standard  
Glucoraphanin, glucoerucin and sinigrin standard stock solutions were prepared in 
water/methanol 50:50 (v/v) at a concentration of 5 mg/ml and stored at -20 °C. 
Standard working solutions were prepared by dilution of the stock solutions in 
water/methanol 50:50 (v/v), in order to obtain concentrations ranging from 5 to 500 
µg/ml. These working solutions were stored at 4 °C and used at most for a week. 
Quality controls (QCs) at concentrations 1.7, 6.7 and 16.7 µg/ml were prepared before 
analysis by dilution of the working solutions in 5:95 (v/v) formic acid 0.5 % in 
acetonitrile/formic acid 0.5% in water. 
Concerning isothiocyanates, sulforaphane and erucin stock solutions were prepared 
dissolving precise amounts of standard sample into acetonitrile, obtaining a final 
concentration of 2.5 mg/ml. These stock solutions were stored at -20 °C. Standard 
working solutions were prepared by dilution of stock solutions in acetonitrile, 
obtaining a final concentration in the range 5 – 250 µg/ml. These working solutions 
were stored at 4 °C at most for three days. Quality controls (QCs) at concentrations 
16.7, 125 and 200 µg/ml were prepared before analysis by dilution of the working 
solutions in 5: 95 (v/v) formic acid 0.5 % in acetonitrile: formic acid 0.5% in water. 
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2.3.3 Liquid chromatography and mass spectrometry: method 
validation 
Waters Alliance 2690 Chromatograph (Milford, MA, USA) with 120 positions 
autosampler and thermostat was used. Mass spectrometer triple quadrupole and 
electrospray interface (QUATTRO LC, Waters) was used for quali-quantitative analysis 
Analytical separation was conducted on a WATERS X-select CSHTM C18 5.0 µm (2.1 
mm*150 mm) column 
 
2.3.3.1 HPLC optimization 
The mobile phase used to achieve a good separation between the main glucosinolates, 
glucoraphanin (GRA), sinigrin (SIN), glucoerucin (GER) and the main isothiocyanates, 
sulforaphane (SFR) and erucin (ER), was formic acid 0.5 % (v/v) in acetonitrile (solvent 
A) and  formic acid 0.5 % (v/v) in water (solvent B) using a gradient elution (10 min at 
5% A and 4 min at 24% A, 4 min at 50% A, 7 min at 80% A, 5 min at 5%) at 0.15 mL 
min−1 flow rate. The analytical column was maintained at 30°C and the sample volume 
injected was 20 µL. In the optimized analytical conditions, the mean retention times 
were for GRA 6.3± 0.2 min, SIN 8.2 ± 0.2 min, GER 16.9 ± 0.2 min, SFR 17.2± 0.1 min 
and ER 26.8 ± 0.2 min. The total ion chromatogram (TIC) for each analyte was reported 
in Figure 23.  
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Figure 23. Total ionic current (TIC) of A) GLSs B) ITCs 
 
A 
B 
Total ion current 
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2.3.3.2 ES mass spectrometry optimization 
Ionization and revelation parameters were optimized for each analyte (Table 6).  
 
Table 6. Ionization parameters for main Glucosinolates and isothiocyanates 
 
Instrumental parameters  GRA ER SIN  SFR ER 
Ionization mode - - - + + 
Capillary voltage (kV) 3.0 3.0 3.0 3.0 3.0 
Cone voltage (V) 35 35 35 15 15 
Source temperature (°C) 130 130 130 130 130 
Desolvation temperature (°C) 410 410 410 410 410 
Nebulizer rate (L/h) 65 65 65 65 65 
Desolvation rate (L/h) 1065 1065 1065 1065 1065 
RCE (%) a 30 30 30   
Collision gas Ar Ar Ar Ar Ar 
Parent ion (m/z) 436 420 358 178 162 
Daughter ion (m/z) 372 259 162 114 162 
 
 
In Figures 24-28 are reported MS/MS spectra for each analyte with respective 
fragmentation reactions.  
For quantitation, each analyte molecular ion has been used, while for assessing 
specificity has been monitored the most intensive fragmentation reaction using MRM 
acquisition mode. 
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Figure 24. Glucoraphanin MS/MS spectrum 
 
 
 
Figure 25. Glucoerucin MS/MS spectrum  
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Figure 26. Sinigrin MS/MS spectrum 
 
 
 
Figure 27. Sulforaphane MS/MS spectrum 
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Figure 28. Erucin MS/MS spectrum 
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2.3.3.3 Method Validation  
HPLC-ESI-MS/MS method has been validated according to ICH guidelines. 
 
Detection limit (LOD) and quantitation limit (LOQ) 
LOD and LOQ of each analyte, expressed as 3 and 10 times signal to noise ratio 
respectively, have reported in Table 7.  
  
 Table 7. LOD and LOQ values for glucosinolates and isothiocyanates 
 LOD (ng/mL) LOQ (ng/mL) 
GRA 2.5 5.0 
GER 5.0 25 
SIN 25 100 
SFR 50 100 
ER 250 500 
 
 
Linearity range 
Linearity was studied in the range from 0.5 to 50 µg/ml for each glucosinolates and 
from 5 to 250 µg/ml for isothiocyanates.  
Linear calibration curve parameters were obtained from the plot of the analyte peak 
area/internal standard peak area versus analyte concentration using a least squares 
regression analysis (weight = 1/x2). The performance of the analytical method was 
monitored using three quality control samples (QCs) having 4.5 nM for QC low, 20 nM 
for QC med and 45 nM for QC high.  
 
 
  
61 
 
Accuracy (bias %) and Precision (CV %) 
Method precision and accuracy, expressed as bias% and CV% respectively, were 
determined intraday and interday using QCs samples. In Table 8 and in are reported 
intraday and interday precision and accuracy values for glucosinolates and 
isothiocyanates.  
 
Table 8. Precision and accuracy values for glucosinolates and isothiocyanates 
 
 GRA GER SIN 
µg/mL bias (%) CV (%) bias (%) CV (%) bias (%) CV (%) 
Intraday 
1.67 (QC low) 0.92 -0.20 1.01 -9.78 0.38 -8.61 
6.67 (QC med) 1.91 5.60 1.36 -10.0 1.18 -7.91 
16.67 (QC high) 0.59 2.52 3.92 -1.99 1.32 1.86 
Interday 
1.67 (QC low) 2.91 1.60 1.86 -6.99 2.32 -2.20 
6.67 (QC med) 1.67 8.70 2.06 -5.05 1.54 -1.40 
16.67 (QC high) 0.91 4.58 0.58 6.50 1.35 6.68 
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Table 9. Precision and accuracy values for isothiocyanates 
 SFR ER 
µg/mL bias (%) CV (%) bias (%) CV (%) 
Intraday 
16.7 (QC low) 5.4 7.8 9.8 0.6 
125 (QC med) 5.6 -6.6 4.8 -10.4 
250 (QC high) 9.4 3.3 3.9 12.7 
Interday 
16.7 (QC low) 8.7 0.80 9.5 -8.8 
125 (QC med) 3.0 -13.4 4.9 -7.9 
250 (QC high) 3.8 12.6 1.9 8.5 
 
 
2.3.4 Glucosinolates extraction procedures 
The extraction of Broccoli, rocket salad and bakery products were performed in 
collaboration with CRA-CIN of Bologna. 
 
Broccoli and rocket salad  
300-500 mg of seeds or broccoli were ground to a fine powder, incubated in thermal 
bath at 90 °C for 10 minutes in 4 ml EtOH 70% and then sonicated for 30 minutes. 
Extracts obtained were centrifuged for 30 minutes at a speed of 39800 rpm at a 
temperature of +4 °C and then filtered. The remaining flour was washed with 4 ml 
EtOH on vortex for 1 minute and filtered. 
 
Bakery product 
The sample was incubated in a microwave system and analytes extracted setting 400 
Watt as maximum power, heating gradient: 80 °C in 3 minutes and extraction at 80 °C 
for 10 minutes. Extracts were centrifuged at a speed of 25900 rpm at a temperature of 
+4 °C and filtered. The residue was retreated in microwave oven as described above, 
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the extract centrifuged, and filtered. These extracts were left for 48 hours at -20 °C, 
centrifuged for 30 minutes at 39800 rpm at +4 °C. 
 
 
2.4 Results and discussion 
2.4.1 Glucosinolates in rocket salad seeds 
Rocket salad seeds extracts contain mainly glucoerucin and glucoraphanin, but in 
different amounts ( 
Figure 29). Two different kinds of seeds were analyzed: pressure disoiled seeds and 
hexane disoiled seeds. In particular, glucoraphanin amounts are about 0.5 µmol/g and 
1.0 µmol/g, respectively, in pressure disoiled seeds and hexane disoiled seeds, while 
glucoerucin is about 90 µmol/g in both seeds. From these data arise that disoiling 
process influence the amount of glucoraphanin but not the amount of glucoerucin. 
Further analysis showed that a preliminary autoclaving process decrease the extraction 
yield of glucoerucin, but not of glucoraphanin, about of the 15%. Sinigrin concentration 
is under the LOD in all the samples analyzed.  
 
 
 
Figure 29. TIC of rocket salad seed extract 
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Before the analysis on samples, matrix effect (EM%) was evaluated for glucosinolates. 
For this purpose, samples spiked with known concentration of standard were analyzed 
and the recovery of the analyte was determined subtracting from the obtained value 
the endogen contribute. E.M.% values close to 100% show absence of matrix effect, 
higher and lower values than 100% indicate, respectively, ionic increase or ionic 
suppression. 
Matrix effects (Table 10) are calculated as ratio of glucosinolate concentration in 
matrix and glucosinolate concentration in mobile phase. 
 
Table 10. Matrix effect of GLSs in rocket seed 
E.M. % ± DS in rocket seeds 
µg/ml GRA GER SIN 
1.67 (QC low)  104 ± 1.1 103 ± 4.3 104 ± 0.7 
7.20 (QC med) 104 ± 1.7 101 ± 1.5 102 ± 1.5 
16.7 (QC high) 101 ± 0.2 97 ± 1.5 100 ± 0.7 
 
 
2.4.2 Glucosinolates in broccoli sprouts 
Glucosinolates composition in broccoli is quite complex and very different from rocket 
seeds. Indeed, there are both aliphatic, as glucoiberin, epiprogoitrin, and aromatic 
glucosinolates, as glucobrassicin and neoglucobrassicin (Figure 30). These 
glucosinolates were not quantified, because their standards were not available. 
Concerning glucoraphanin, glucoerucin and sinigrin, their amount in broccoli extracts 
were 0.82, <LOD and 0.2 µmol/g respectively.  
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Figure 30. TIC of broccoli extract sample 
 
Matrix effect in broccoli extract was evaluated for each analyte and results, expressed 
as %, are reported in Table 8. As reported, matrix effect in broccoli extract is negligible.  
 
 
Table 11. Matrix effect of GLSs in broccoli extracts 
E.M % ± DS in broccoli extracts 
µg/ml GRA GER SIN 
1.67 (QC low)  101 ± 2.7 108 ± 0.6 98.4 ± 1.4 
7.20 (QC med) 103 ± 2.0 98 ± 2.9 102 ± 4.0 
16.7 (QC high) 103 ± 1.9 99 ± 2.1 102 ± 1.8 
 
 
2.4.3 Glucosinolates in bakery products  
Bakery products extracts analyzed were obtained from two different flours. 
Specifically, in the first preparation was used a flour in which myrosinase is active, and 
one in which the myrosinase is deactivated.    
In Figure 31 was reported the total ion current of the two different bakery products. As 
observed, using the flour in which the myrosinase is active, the glucoerucin and 
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glucoraphanin amount was 0.1 µmol/g and <LOQ respectively. Unlike in the bakery 
product containing deactivated myrosinase flour the glucoerucin amounts was 10 
times higher than that present in activated myrosinase flour (i.e. 1.2 µmol/g) and the 
amount glucoraphanin was 0.04 µmol/g.  
Likely, during the fortification process and/or during the extraction GLSs could react 
with the myrosinase present in the flour, reducing their amount in the bakery product.    
 
 
 
 
Figure 31. TIC of bakery product extract samples 
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2.5 Conclusions 
An HPLC-ES-MS/MS method for the simultaneous determination of glucosinolates and 
isothiocyanates has been developed and optimized. This method has been validated 
according to ICH guidelines and is very sensitive and selective (GLSs LOQ< 100 ng/mL; 
ITCs <500ng/mL for each analytes), precise and accurate (bias % and CV% <10% for 
each analytes) and the matrix effect was less than 10% for each analytes. 
This method is used to quantify the GLSs and ITCs present in rocket salad seeds, 
broccoli extract and also in bakery products.  
The new developed method could replace the ISO 9167-1 method currently used 
based on an indirect quantitation of GLSs. Indeed, in the ISO method GLSs must be 
preliminary converted into desulphoglucosinolates, with reaction times up to three 
days and the risk of uncontrolled recovery of the derivative. Moreover the use of mass 
spectrometer in the developed method, in particular the MRM date acquisition mode, 
allow the elimination of many interferences in the matrix, increase sensitivity and 
selectivity and allow to separate partially co-eluting species acting also directly on the 
sample without any pre-analytical step.  
This method could greatly optimize analysis time and could be applied into food 
industry for a quick and efficient quantification of these analytes into different 
matrices. 
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Chapter 3 
Drugs co-administration: OCA and bile 
acid sequestrants  
Drug-drug interactions could results in different systemic exposure, causing variations 
in the activity of co-administered drugs. The simultaneous administration of two drugs 
could be synergistic (when the drug's effect is increased) or antagonistic (when the 
drug's effect is decreased) or a new effect can be produced.  However, interactions 
may also exist between drugs and foods, as well as drugs and medicinal plants or 
herbs.  
The drug-drug interaction may also increase the risk of side effects. On the other hand, 
if the action of a drug is reduced it may break off the therapeutic effect because of 
under dosage. 
Therefore, the preliminary evaluation of potential drug interactions is important 
before the market approval as well as during the post-marketing period. 
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3.1.1 Obeticholic acid: pharmacological activity, metabolism 
and physicochemical properties 
Obeticholic acid (OCA, Figure 32) is a semi-synthetic analogue of the primary bile acid 
(BA) chenodeoxycholic acid (CDCA), which is a natural ligand of the nuclear hormone 
receptor farnesoid X receptor (FXR).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Chemical structures of OCA and CDCA and their taurine and 
glycine conjugates 
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FXR constitutes a negative feedback regulator in the hepatic synthesis of BAs from 
cholesterol through the repression of cholesterol 7α- hydroxylase (CYP7A1). This step 
is a limiting step of the entire biosynthesis, conjugation and transport of BAs. 
Activation of FXR inhibits BA synthesis and protects against the toxic accumulation of 
BAs.  
OCA is undergoing development in phase 2 and 3 studies for specific liver and 
gastrointestinal disorders, as primary biliary cirrhosis (PBC).  
PBC is an autoimmune liver disease, in which the destruction of the bile ducts that 
transport bile acids out of the liver, resulting in cholestasis, was observed.  
If untreated, or if a patient does not adequately respond to treatment, chronic 
inflammation and fibrosis can advance to cirrhosis liver failure, and death. 
There is no known cure for PBC but previous studies suggested that treatment with 
FXR agonists should be beneficial. The agonist potency (EC50) of OCA was 100 times 
higher than its endogenous analogue (0.15 vs 15 µM)44.   
The metabolism of OCA is quite similar to CDCA (Figure 32). Indeed, study in vivo 
reports that OCA was mainly metabolized in glycine (OC-gly) and taurine (OC-tau).  
Concerning the physicochemical properties of OCA, they are quite similar to CDCA, 
including solubility, lipophilicity and critical micellar concentration (Table 12) as well as 
their metabolites. 
 
Table 12. Physicochemical properties of OCA, CDCA and their metabolites 
 
CDCA CDC-gly CDC-tau OCA OC-gly OC-tau 
Solubility 
(µM) 
32 7 h.s. 9 1.3 h.s. 
CMC 
(mM) 
3.2 2.0 3.0 2.9 1.7 1.8 
LogPA- 2.2 0.4 0.9 2.5 0.6 1.0 
h.s. high solubility 
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3.1.2 Bile acids sequestrants: cholestyramine and colesevelam 
The bile acid sequestrants (called also resins) are polymeric compounds used in the 
treatment of chronic diarrhea due to bile acid malabsorption and/or in the therapy of 
pruritus associated with cholestasis. Indeed, bile acid sequestrants bind BA) in the 
gastrointestinal tract modifying their enterohepatic circulation and preventing their re-
absorption from the gut.  In addition to BAs, bile acid sequestrants could also bind 
drugs in the GI tract, preventing their absorption into the bloodstream. For this reason, 
it is generally advised that they could be spaced several hours apart from other drugs. 
The main bile acid sequestrants on the market are cholestyramine and colesevelam ( 
Figure 33), active pharmaceutical ingredients of Winthrop and Welchol respectively.  
The interaction of these resins with BA (sequestrant) increases the conversion of 
Cholesterol to BA as a negative feedback mechanism resulting also in a reduction of 
cholesterol in the body. 
Cholestyramine is a strong ion exchange resin, in which its chloride anions exchange 
with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin 
matrix. Its anion functional group is a quaternary ammonium group attached to an 
inert styrene-divinylbenzene copolymer. 
Colesevelam hydrochloride is made by crosslinking polyallylamine with 
epichlorohydrin, and then modifying it with bromodecane and (6-bromohexyl) 
trimethylammonium bromide. The bromide ions are then replaced with chloride ions 
when the material is washed45. 
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Figure 33. Structure of A) Cholestyramine B)Colesevelam 
 
 
3.1.3 Adsorption isotherms 
Adsorption isotherm describes the equilibrium of the sorption of a compound at a 
surface when the temperature is constant. It represents the amount of material bound 
(qe) at the surface as a function of the material present in solution. The most 
frequently used isotherms46 are the linear isotherm, Freundlich isotherm, and the 
Langmuir isotherm.  
Linear isotherm 
Formally the linear adsorption isotherm resembles Henry's law. The linear isotherm 
(Equation 1) can be used to describe the initial part of many practical isotherms. In this 
case, the amount of analytes absorbed at equilibrium (qe) is proportional to the 
concentration of analyte unabsorbed in solution at equilibrium (Ceq) in the solution at 
equilibrium with a the distribution coefficient (Kd). 
 
 
  
𝑞𝑒 =  𝐾𝑑 ∙ 𝐶𝑒𝑞  
Equation 1. Linear isotherm 
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Freundlich isotherm 
Freundlich isotherm is commonly used to describe the adsorption for the 
heterogeneous surface based on the empirical equation (Equation 2).  
 
 
 
 
The constant KF is an approximate indicator of adsorption capacity, while 1/n is a 
function of the strength of adsorption in the adsorption process.  
If n=1 then the partition between the two phases are independent of the 
concentration and this expression reduces to a linear adsorption isotherm.  If value of 
1/n is below one it indicates a normal adsorption while when 1/n is above one it 
indicates cooperative adsorption. The function has an asymptotic maximum as 
pressure increases without bound.  
 
Langmuir isotherm  
The Langmuir isotherm describes quantitatively the formation of a monolayer 
adsorbate on the adsorbent surface between solid and liquid phases. 
The model assumes that 1) all of the adsorption sites are equivalent and each site can 
only accommodate one molecule; 2) the surface is energetically homogeneous and the 
adsorbate-adsorbate interaction is considered negligible compared to the interactions 
of adsorbate-adsorbent; 3) there are no phase transitions. Based upon these 
assumptions, Langmuir represented in Equation 3. 
 
 
 
 
Where qm is the maximum adsorption capacity and b the affinity of sorbent for the 
analytes.  
𝑞𝑒 =
𝑞𝑚 𝑏 𝐶𝑒𝑞
1 + 𝑏 𝐶𝑒𝑞
 
𝑞𝑒 =  𝐾𝐹 ∙ 𝐶𝑒𝑞
1/𝑛
 
Equation 3. Langmuir isotherm 
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3.2 Aim and rationale 
In the treatment of PBC, a new semisynthetic bile acid, the obeticolic acid (OCA) has 
been developed. PBC is a liver disease that primarily results from autoimmune 
destruction of the bile ducts that transport bile acids (BAs) out of the liver, resulting in 
cholestasis. Previous studies suggested that treatment with FXR agonists should be 
beneficial in cholestatic diseases as PBC. Among them, OCA has shown agonist potency 
(EC50) more 100 times higher than that of its endogenous analogue CDCA44. A 
common symptom of PBC is itch caused by BAs in circulation which would normally be 
removed by the liver.  
To relieve itching, a bile acid sequestrant, as cholestyramine and colesevelam, are 
prescribed to absorb BAs in the gut and be eliminated.  
During the development of a new drug, the interaction drug-to-drug had to be 
investigated especially when two or more drugs are used in combination to treat a 
disease or condition, as required by FDA. 
Regarding the treatment of PBC, the therapeutic effect of OCA could be reduced by a 
co-administration of BAs sequestrant. Indeed, OCA could be adsorbed by BAs 
sequestrant and not only the endogenous bile acids.   
For this reason, the aim of this work is the development of an in vitro model for the 
determination and quantification of the interactions between OCA and colesevelam 
and cholestyramine in terms of maximal binding capacity (qm) and affinity adsorbent 
(b) to the OCA and its main metabolites.  
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3.3 Experimental 
3.3.1 Materials and reagents 
Cholestyramine was purchased from Sigma Aldrich, and Colesevelam was a kind gift of 
Daiichi Sankyo (courtesy of Dr. Ken Jones). OCA and its glycine and taurine N-
acylamidates (conjugates) were provided by the Department of Pharmaceutical 
Science, University of Perugia, Italy.  CDCA and its glycine and taurine conjugates and 
BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) were purchased from Sigma 
Aldrich.   
 
 
3.3.2 HPLC-ES-MS/MS method  
Bile acid concentration was determined by HPLC-ES-MS/MS in the following 
experimental conditions: 
HPLC column: Phenyl-hexyl column (XSelect) 4µm, 150 x 2.1 mm 
Mobile phase composition and elution mode: Solvents A is a 15 mM ammonium 
acetate buffer (pH = 8.00) and Solvent B was acetonitrile: methanol = 75:25 v/v 
 
Time (min) A% B% 
Flow 
(ml/min) 
Curve 
0 65 35 0.15 1 
10 65 35 0.15 1 
10.3 55 45 0.15 6 
21 55 45 0.15 1 
21.3 0 100 0.15 6 
23.3 0 100 0.15 1 
24 65 35 0.15 6 
35 65 35 0.15 1 
The HPLC was connected to an Quattro-LC (Micromass) MS system operating in the 
negative ion mode with a MRM acquisition method with the following parameters: 
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Instrumental parameters Value 
Capillary 3.0 KVolts   
Cone   
OCA 70   
OC-gly 60   
OC-tau 85   
Extractor 8 volts   
RF lens 0.07 volts   
Source block temp. 130ºC   
Desolvation temp. 200ºC   
MS  MS2 
Entrance 1.0 volts Entrance: 0.0 volts 
Exit 1.0 volts Exit: 1.0 volts 
Ion energy 1.5 volts Ion energy: 3.0 volts 
LM resolution 12 LM resolution: 12 
HM resolution 12 HM resolution: 12 
Pressure    
Analyser vacuum 4.2e-5 mBar   
Gas cell 2.4e-3 mBar   
Flows    
Nebulizer (Nitrogen) 87 lit/hr   
Desolvation gas (Nitrogen) 800 lit/hr   
Multiplier 650 volts   
 
For OCA the transition m/z 419.5  419.5 was monitored (no fragmentation product 
ions were observed). For the glycine conjugate of OCA (OC-gly) the transition m/z 
476.2  73.8 was monitored. This fragment is typical of the loss of the glycine moiety. 
For OC-tau the transition m/z 526.2  79.9 was monitored. This fragment is typical of 
the loss of the taurine moiety.  
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The used method has been validated and fulfilled all the standard criteria of accuracy, 
precision; the LOQ was adequate to evaluate the concentration of the different BA in 
the analyzed solutions44.  
 
 
3.3.3 Adsorption experiments of bile acids by bile acid 
sequestrants 
Since one of the assumptions of the Langmuir isotherm provides that the adsorbate-
adsorbate interaction is considered negligible compared to adsorbate-adsorbent 
interactions, it was decided to work in a range of concentrations below the critical 
micellar concentration (CMC) to avoid that the binding with the resin might be 
hindered  by the micelles formation.   
BA sorption experiments were carried out in BES (N,N-Bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid) 0.05M pH=7.2. BES is a zwitterionic buffer that has no 
affinity for bile acid sequestrants. The dry BA sorbent (0.003g), i.e. cholestyramine or 
and colesevelam, was suspended in the buffer solution (V, 3mL) with a given initial 
concentration of BA (C0), covering the range of 0.3-1.5mM. The mixture was rigorously 
stirred for 24h at 37°C. Then the suspension was centrifuged, appropriately diluted and 
analyzed. 
The amount of BA bound was calculated as the difference between the total amount 
of bile acids introduced into the system and the amount of unabsorbed bile acid. The 
maximum binding capacity of each sequestrant was calculated according to the 
Langmuir isotherm equation:  
 
 
where: 
 
Qe amount of BA absorbed at equilibrium (mmol/g) 
Qm maximum adsorption capacity (mmol/g) 
𝑞𝑒 =
𝑞𝑚 𝑏 𝐶𝑒𝑞
1 + 𝑏 𝐶𝑒𝑞
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B affinity of sorbent for BA (mM-1) 
Ceq concentration of unabsorbed BA  in solution at equilibrium (mM) 
 
The values of qm and b were determinated by plotting 1/qe versus 1/ Ceq:  
 
 
 
 
1
𝑞𝑒
=
1
𝑞𝑚𝑏
1
𝐶𝑒𝑞
+
1
𝑞𝑚
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3.4 Results and discussion 
3.4.1 Adsorption experiments of bile acids by bile acid 
sequestrants 
Cholestyramine 
The adsorption isotherms for the binding of OCA and CDCA and its glycine and taurine 
conjugates to cholestyramine are shown in Figures 34-36. The maximum adsorption 
capacity (qm) for OCA, OC-tau and OC-gly was very similar to that of the corresponding 
endogenous bile acids (Table1) while their affinity for of cholestyramine was greater 
than those of the endogenous bile acids (CDCA, CDC-gly, and CDC-tau).  
Indeed, the affinity of cholestyramine for OCA was 5.3 times greater than CDCA, for 
OC-gly was 1.5 times greater than CDC-gly and for OC-tau was 2.0 times greater than 
for CDC-tau. 
It has been demonstrated that the forces involved in bile salt anion-cholestyramine 
interaction are primarily of electrostatic nature but are reinforced by an additional 
nonelectrostatic interaction of the hydrophobic face of the steroid nucleus of bile acids 
with the hydrophobic portion of the resin; the strength of the latter force is dependent 
on the degree of hydrophobicity of the adsorbate molecule. Therefore, the additional 
6α-ethyl group in OCA, and its conjugates is the likely explanation for its greater 
affinity for the sequestrants.  
In a previous study we measured the 1-cotanol/water partition coefficient LogPo/w of 
OCA, and observed that is was greater than that of CDCA -- 2.5 vs 2.2 -- further 
supporting the involvement of nonelectrostatic interactions. 
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Figure 34. A) Adsorption isotherms for binding of OCA (○ ) and CDCA (■) to 
cholestyramine B) Langmuir isotherms for the adsorption of OCA (○) and CDCA (■) to 
cholestyramine 
 
 
 
Figure 35. Adsorption isotherms for binding of OC-gly (○) and CDC-gly (■) to 
cholestyramine B) Langmuir isotherms for the adsorption of OC-gly (○) and CDC-gly (■) 
to cholestyramine 
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Figure 36. A) Adsorption isotherms for binding of OC-tau (○) and CDC-tau (■) to 
cholestyramine B) Langmuir isotherms for the adsorption of OC-tau (○) and CDC-tau 
(■) to cholestyramine 
 
Table 13. Coefficients of adsorption isotherms obtained for cholestyramine 
Cholestyramine CDCA OCA CDC-gly OC-gly CDC-tau OC-tau 
Slope 0.17 0.050 0.093 0.060 0.057 0.029 
Intercept 0.398 0.393 0.353 0.349 0.321 0.321 
qm (mmol/g) 2.5 2.5 2.8 2.9 3.1 3.1 
b (mM-1) 2.3 12.3 3.8 5.8 5.6 11.2 
 
The comparison between the adsorption isotherms for the binding of OCA, OC-tau and 
OC-gly to cholestyramine was reported in Figure 37. The maximum capacity for OCA, 
OC-gly and OC-tau was very similar, while the affinity of cholestyramine for OCA was 
greater than its taurine and glycine conjugates, respectively 1.1 times and 2.1 times.  
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Figure 37. Adsorption isotherms for binding of OCA (○ ), OC-gly (□ ) and OC-tau (▲ ) to 
cholestyramine 
 
 
Colesevelam 
The adsorption isotherm for the binding of OCA and CDCA and its glycine and taurine 
conjugates to colesevelam were reported in Figure 38-40. The maximum adsorption 
capacity (qm) for OCA, OC-tau and OC-gly is was very similar to respective endogenous 
bile acids (Table2) while their affinity of colesevelam was greater than that of CDCA. 
Indeed, the affinity of colesevelam for OCA is 2.8 times greater than CDCA, for OC-gly 
is 1.9 times greater than CDC-gly and for OC-tau is 1.5 times than CDC-tau.  
83 
 
 
Figure 38. A) Adsorption isotherms for binding of OCA (○ ) and CDCA (■) to 
colesevelam B) Langmuir isotherms for the adsorption of OCA (○ ) and CDCA (■) to 
cholestyramine 
 
 
 
Figure 39. A) Adsorption isotherms for binding of OC-gly (○) and CDC-gly (■) to 
colesevelam B) Langmuir isotherms for the adsorption of OC-gly (○) and CDC-gly (■) to 
colesevelam 
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Figure 40. A) Adsorption isotherms for binding of OC-tau (○) and CDC-tau (■) to 
colesevelam B) Langmuir isotherms for the adsorption of OC-tau (○) and CDC-tau (■) to 
colesevelam 
 
 
Table 14. Coefficients of adsorption isotherms obtained for colesevelam 
Colsevelam CDCA OCA CDC-gly OC-gly CDC-tau OC-tau 
Slope 0.024 0.007 0.030 0.0123 0.027 0.0126 
Intercept 0.657 0.535 0.610 0.471 0.636 0.4513 
qm (mmol/g) 1.5 1.9 1.6 2.1 1.9 2.1 
b (mM-1) 27.4 76.3 20.3 38.3 23.5 35.8 
 
The adsorption isotherms for the binding of OCA, OC-tau and OC-gly to colesevelam 
are shown in Figure 41. The affinity of colesevelam for OCA was greater than those of 
its taurine and glycine conjugates, respectively 2.1 times and 2.0 times while the 
maximum capacity was very similar.  
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Figure 41. Adsorption isotherms for binding of OCA (○ ), OC-gly (□ ) and OC-tau (▲ ) to 
colesevelam 
 
 
3.4.2 Comparison between   colesevelam and cholestyramine 
adsorption  
The adsorption isotherms for the binding to colesevelam of OCA and CDCA and its 
glycine and taurine conjugates compared with cholestyramine were reported in Figure 
42. The maximum capacity of OCA, OC-tau and OC-gly was slightly greater for 
cholestyramine than colesevelam while the affinity of bile acids for colesevelam was 
much greater than that of cholestyramine 6.2 times for OCA, 6.6 times for OC-gly and 
3.2 times for OC-tau.  
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Figure 42. Comparison of the adsorption isotherms of OCA to cholestyramine (blu) and 
colesevelam (red) 
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3.5 Conclusions 
The results of these adsorption experiments indicate that OCA, OC-tau and OC-gly 
exhibited greater binding to the bile acid sequestrants, colesevelam and 
cholestyramine, than their corresponding endogenous bile acids CDCA, CDC-tau and 
CDC-gly. The implication of these findings is that dosing of bile acid sequestrants at the 
same time as that of OCA is likely to decrease the intestinal absorption of OCA.  In 
addition, the sequestrants will also bind the glycine and taurine conjugates of OCA and 
therefore active also under steady-state chronic regiments.  
In conclusion the co-treatment of OCA and the bile acid sequestrant must be avoided 
in order to maintain the appropriate level of OCA in the enterohepatic circulation. The 
co-treatment is also no recommended by administering the two drugs at different time 
since the sequestrant are able to bind efficiently also the active metabolites of OCA i.e. 
OC-gly and OC-tau.  
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Chapter 4 
Electron ionization in LC-MS:    
Direct-EI-UPLC-MS for sterols analysis 
Nowadays, commercially available liquid chromatography-mass spectrometry (LC-MS) 
interfaces are based on atmospheric pressure ionization techniques (API). Among 
them, electrospray (ESI) and atmospheric pressure chemical ionization (APCI) are the 
most common ionization sources.  
Nevertheless, these soft ionization sources show few, critical restraints47,48. Firstly, the 
signal response of ESI and APCI is strongly influenced by the polarity and ionization 
properties of the analytes. ESI and APCI, indeed, are suitable for compounds 
characterized by a medium-high polarity while less polar molecules request a chemical 
derivatization before the analysis to introduce functional group prone to ionization. 
Secondly, the structural information obtained with these sources could be insufficient 
especially for unknown substances since the quasi-intact molecular ion is produced. 
Therefore, the coupling with tandem MS (MS-MS) or MSn is required to obtain more 
information on structure by further ionize and fragment the ion. However, there are 
not MSMS electronic libraries to match the mass spectra obtained. Furthermore, the 
quantitative analysis in ESI and APCI is often influenced by matrix effects causing an 
under or over-estimation.  
The solution of these problems could be the LC and electron ionization-mass 
spectrometry (EI-MS) coupling47,48. Indeed, EI is not influenced by the polarity of the 
analyte and its mass spectra represent a real chemical fingerprint for each molecule. 
Fragments, molecular-ion abundance and their biodistribution in the EI mass spectrum 
are unique, highly reproducible and collected in electronic libraries (NIRST, National 
Institute of Standard and Technology).   
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Unfortunately, LC and EI-MS seem to be incompatible “unfriendly” analytical 
techniques. Indeed, EI operates in high-vacuum and the presence of liquid effluent 
could make it instable, decreasing the instrument performance. The solvent 
elimination represents the main obstacle in the LC-EI-MS coupling because it should be 
performed without influencing the sample ionization. The first device that combine EI 
and HPLC was developed in 1984 by Willoughby and Browner and it based on a particle 
beam (PB) interface in which the solvent was eliminated through a gas-phase 
momentum separation. Despite initial success of PB interface, this interface was 
quickly abandoned because of its scarce sensitivity, signal instability and limited 
linearity especially in reverse phase. The coupling between LC and EI-MS was forgotten 
for ages but recently two different approaches, supersonic molecular beam (SMB) and 
Direct-EI interface, was proposed.  
 
4.1 Direct-EI interface47,48 
Direct-EI interface was designed and totally realized in Italy at University of Urbino and 
nowadays it is commercially available combined with nano-LC systems.  
The name “Direct-EI” was chosen to emphasize the direct connection between the LC-
column and EI ion source without intermediate apparatus. Indeed, in the Direct-EI 
interface, fused silica capillary tubing connects the separation system with EI source 
passing from an atmospheric pressure region to high vacuum. In this way the transition 
between liquid to gas phase is carried out inside the EI.  
The interface mechanism is based on an aerosol formation in high-vacuum condition 
followed by a quick droplet desolvation and analyte vaporization. Once the transition 
from liquid to gas phase is completed, the mix of vapors homogeneously distributed 
inside source block are exposed to the “impact” of the electron beam (Figure 43).  
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The temperature of the ion source was usually settled between 300 and 400°C to 
compensate for the latent heat of vaporization during the droplet desolvation and to 
convert the solute into the gas phase. 
The separation module coupled with Direct-EI should operate at nano-scale flow rate 
(100-500 nL/min) without exceeding the 750 nL/min, in order to obtain the best 
analytic performance. This strict dependence on nano-flow represents the main 
restraint in the use of Direct-EI LC-MS interface. Indeed, the most nano-LC systems are 
less widespread in a analysis laboratory than HPLC or UHPLC. The new challenge in the 
research focused on Direct-EI is its coupling with UHPLC systems operating at higher 
flow rate (200-500 µL/min) without significant performance decreases. Several 
splitting devices are currently tested to optimize the best split ratio49.  
 
 
 
 
 
 
Figure 43. Direct-EI interface 
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4.2 Aim and rational  
Steroids are a big family of small molecules with a wide polarity range starting from 
neutral liphofilic sterols including cholesterol and its close metabolites or intermediate, 
steroid hormones and acidic ionized steroid such as bile acids. One of the main 
challenges in steroids analysis is develop high sensitivity LC-MS methods without 
derivatization and mobile phase additives. These pretreatments are often necessary 
because compounds less polar as steroids could be not efficiently ionized by soft 
ionization source conventional coupled with LC-MS system.  
The use of Direct-EI-LC-MS in steroids analysis of can offer several advantages in 
comparison with current GC and HPLC-MS method: i) the sample preparation 
procedures can be carried out without derivatization; ii) the signal response is not 
influenced by the polarity of the analytes and not affected by matrix effect; iii) a more 
complete structural information can be obtained from EI-MS spectrum due to the high 
fragmentation and the comparison with electronic library.  
This work represents a feasibility studied focused on the optimization of Direct-EI-
UHPLC-MS methods for the determination of impurity profiling of 17β-estradiol (Figure 
44) steroids analysis and the simultaneous determination of nonalcoholic 
steatohepatitis (NASH) biochemical markers50 as cholesterol, desmosterol and 
lathosterol (Figure 45).  
 
 
 
 
 
 
 
 
Figure 44. Chemical structures of 17β-estradiol and its impurities 
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Figure 45. Nonalcholic Steatopepatitis biomarker 
 
4.3 Preliminary data  
Direct-EI-UHPLC-MS method 
Liquid chromatography was carried out with an Agilent 1290 Infinity UHPLC system. A 
splitting device allowed to adapt the UHPLC flow rate (200-500 µL/min) using a 1:500 
ratio. An Agilent 7000A QQQ mass detector was equipped with a Direct-EI interface. 
The splitting device was placed at the interface entrance and right after the injector. 
All standards were injected individually in flow injection analysis (50:50 v:v H2O:ACN) 
to record their mass spectra. Injection volumes spanning from 2 to 10 µL were 
delivered with autosampler. Scan experiments were performed from m/z 80 to 600, 
2.4 cycles/sec. The ion source temperature was set at 350°C. 
Standard solutions of 17β-estradiol and its impurities (6-oxo-17β-estradiol; 17α-
estradiol; 6,7-didehydroestradiol; 9,11-didehydroestradiol; estrone; 4-methylestradiol) 
and for nonalcoholic steatohepatitis biomarkers (cholesterol, lathosterol and 
desmosterol) were prepared in ethanol at 50 µg/mL and directly injected to verify 
signal response and to record their EI-MS spectra. 
 
Preliminary data and future perspective 
EI-MS experimental spectra obtained for 17β-estradiol, 17α-estradiol, estrone, 
cholesterol, lathosterol and desmosterol are compared with NIRST EI-MS spectra, 
showing a matching >70% while the EI-MS spectra of the other 17β-estradiol 
impurities are not present in electronic library.  
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Regarding the determination of 17β-estradiol purity by HPLC-ES-MS or HPLC-UV, in 
previous studies 6,7 and 9,11-didehydroestradiol chromatographic separation is not 
reached51. Since their EI-MS spectra (Figure 46) are significantly different using direct-
EI-LC-MS, they could be accurately quantified as well as for lathosterol and cholesterol 
(Figure 47). 
In conclusion, the results demonstrated that Direct-LC-EI-MS can be successfully 
applied for sterol analysis showing several advantages.  
In particular, the coupling of direct-EI- MS and LC may provide legally defensible, 
reproducible and easy-to interpret mass spectra for the unambiguous identification 
during impurity profiling of 17β-estradiol in pharmaceutical preparation with no matrix 
effects.  
The development and validation of Direct-EI-UHPLC-MS methods are currently carried 
out both for 17β-estradiol and its impurities. This method will be applied to the 
determination of 17β-estradiol purity in pharmaceutical tablet and its chemical 
stability after stress tests in which its degradation products will be identified and 
characterized.    
Concerning NASH biomarkers, their quali-quantitative composition in plasma may be 
simultaneously evaluated avoiding derivatization and matrix effect thus facilitate the 
clinical utility of this analysis.  
Direct-EI-UHPLC-MS allows to reduce significantly the analysis time and the amount of 
plasma sample required, thus stimulating its use in bioanalitical chemistry.   
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Figure 46. EI-MS spectra of A)6,7-didheydroesradiol B) 6,7-didheydroesradiol 
95 
 
 
 
 
  A 
B 
Cholesterol 
Lathosterol 
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 %
 
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 %
 
m/z 
m/z 
Figure 47. EI-MS spectra of A) cholesterol B) lathosterol 
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